Search NLS News

The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.

Professor Ylva Engström was recently re-elected as Chair of the Board of Science for Life Laboratory (SciLifeLab) and NLS asked her about her career, her efforts, and her advice to other women in life science.

The company has been granted a US patent for its SiPore platform technology.

The two companies have decided to terminate the partnership agreement, covering the rights for Orexo to commercialize the digital mental health program for depression, Deprexis, in the US.

In today’s rapidly shifting global landscape, it’s clear that the future of humanity hinges on how we invest in people, particularly leaders, right now. 

Mentice has appointed Frans Venker as its new Chief Executive Officer, effective January 1, 2025.

ScandiDos has announced that the prestigious Hospital Central de la Defensa Gómez Ulla (HCD Gómez Ulla) in Madrid has become a reference center for ScandiDos and the Delta4 family of products.

Abera Bioscience has received the final decision to approve its patent application “Display of heterologous molecules on bacterial cells and membrane vesicles” from the European Patent Office (EPO).

Anocca has announced the submission of its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase I/II multi-asset umbrella trial, VIDAR-1.

The rightsizing is expected to result in redundancy of approximately 20 percent of the employees across the CELLINK organization.